The woman, surnamed Chen, went to a clinic because of a toothache on July 31. The doctor prescribed a clindamycin phosphate injection to Chen, but several minutes after Chen received the injection, she went into shock and fell into a coma.

Recently, a clindamycin phosphate glucose injection produced by Anhui-based Worldbest Bio-pharmaceutical Co, also known as Xinfu, is suspected of killing six people across the country. China's government banned the use of Xinfu last week.

Chen was sent to a local hospital and came around on August 1 after a 30-hour rescue. However, her brain was seriously injured because of the coma, so she was transferred to a hospital affiliated with the armed police force to receive hyperbaric oxygen therapy. It's still unclear whether Chen will have any sequelae as a result of the coma.

The Hangzhou Food and Drug Administration has launched an investigation for this issue and will check the quality of these drugs.

Liu Jingbo, the office director of the administration, said the investigation will last two weeks and the results are expected to be published around August 15.

Guo Taihong, the director of the administration, said that it is still unclear whether Chen's reaction is related to the quality of the drug, because other reasons, such as improper use of drugs, may also cause adverse reactions.

The drug hasn't been found to bring any adverse reactions to other patients in Hangzhou and is still in use.

China yesterday announced three more deaths linked to Xinfu.

The Ministry of Health announced today that health departments at all levels should report any adverse reaction related to Xinfu to authorities before 4pm everyday starting tomorrow.

The Adverse Drug Reaction Monitoring Center of the State Food and Drug Administration had received 81 reports of severe reactions to Xifu from 10 provinces by Saturday.

The administration has sent a team of experts to investigate the link between the reactions and the antibiotic.